PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTenofovir alafenamide
Vemlidy(tenofovir alafenamide)
Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Tenofovir Alafenamide, Vemlidy (tenofovir alafenamide) is a small molecule pharmaceutical. Tenofovir alafenamide was first approved as Genvoya on 2015-11-05. It is used to treat chronic hepatitis b in the USA. It has been approved in Europe to treat hepatitis b and HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
urogenital diseasesD000091642
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Tenofovir alafenamide, Vemlidy (discontinued: Tenofovir alafenamide)
Combinations
Biktarvy, Descovy, Emtricitabine tenofovir alafenamide, Genvoya, Odefsey, Symtuza (discontinued: Emtricitabine tenofovir alafenamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Darunavir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
SYMTUZAJohnson & JohnsonN-210455 RX2018-07-17
1 products, RLD, RS
Bictegravir sodium
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
BIKTARVYGilead SciencesN-210251 RX2018-02-07
2 products, RLD, RS
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
DESCOVYGilead SciencesN-208215 RX2016-04-04
2 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
GENVOYAGilead SciencesN-207561 RX2015-11-05
1 products, RLD, RS
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
ODEFSEYGilead SciencesN-208351 RX2016-03-01
1 products, RLD, RS
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
VEMLIDYGilead SciencesN-208464 RX2016-11-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
biktarvyNew Drug Application2024-10-17
descovyNew Drug Application2025-01-30
genvoyaNew Drug Application2025-02-03
odefseyNew Drug Application2025-02-24
symtuzaNew Drug Application2024-07-23
vemlidyNew Drug Application2024-04-04
Agency Specific
FDA
EMA
Expiration
Code
EMTRICITABINE / TENOFOVIR ALAFENAMIDE FUMARATE, DESCOVY, GILEAD SCIENCES INC
2029-01-07ODE-457
2024-09-28ODE-284, ODE-285
BICTEGRAVIR SODIUM / EMTRICITABINE / TENOFOVIR ALAFENAMIDE FUMARATE, BIKTARVY, GILEAD SCIENCES INC
2028-10-07ODE-378
2026-06-18ODE-256
2024-02-24M-82
TENOFOVIR ALAFENAMIDE FUMARATE, VEMLIDY, GILEAD SCIENCES INC
2025-10-17NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods
107865182038-07-19U-2978
100397182032-10-06DP
81483742029-09-03DS, DPU-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768
77006452026-12-26DS, DP
Bictegravir Sodium / Emtricitabine / Tenofovir Alafenamide Fumarate, Biktarvy, Gilead Sciences Inc
105488462036-11-08DP
117448022036-11-08DP
97083422035-06-19DS, DP
103850672035-06-19U-257
92169962033-12-19DS, DP
97320922033-12-19DS, DP
87540652032-08-15DS, DPU-257, U-999, U-1259, U-1275, U-1663, U-2352, U-2765, U-3880
92967692032-08-15DS, DPU-257, U-999, U-1259, U-1275, U-1663, U-2352, U-2765, U-3880
73907912025-01-07DS, DP
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc
86332192030-04-30DPU-257
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Alafenamide Fumarate, Odefsey, Gilead Sciences Inc
71258792025-04-21DS, DPU-257
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF13: Tenofovir alafenamide
J05AR: Antivirals for treatment of hiv infections, combinations
J05AR17: Emtricitabine and tenofovir alafenamide
J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
J05AR19: Emtricitabine, tenofovir alafenamide and rilpivirine
J05AR20: Emtricitabine, tenofovir alafenamide and bictegravir
J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
HCPCS
No data
Clinical
Clinical Trials
1302 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20741745018175
Hepatitis bD0065092181813555
HepatitisD006505K75.92181714554
HivD006678O98.7261619544
Chronic hepatitis bD019694EFO_0004239B18.1115139442
Hepatitis aD006506EFO_0007305B15214129440
Acquired immunodeficiency syndromeD000163EFO_0000765B20182210439
Chronic hepatitisD006521K73.911485432
InfectionsD007239EFO_00005445129529
Communicable diseasesD003141266216
Show 36 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis b virusD00651511114
PregnancyD011247EFO_0002950Z33.1123
Drug misuseD000076064112
Virus diseasesD014777B34112
Treatment adherence and complianceD00007482211
CarcinomaD002277C80.011
Hepatocellular carcinomaD006528C22.011
Liver neoplasmsD008113EFO_1001513C22.011
Breast feedingD00194211
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autoimmune diseases of the nervous systemD020274111
SyndromeD013577111
Nervous system malformationsD009421Q00-Q07111
Kidney diseasesD007674EFO_0003086N0811
RecurrenceD01200811
Liver diseasesD008107EFO_0001421K70-K7711
Chronic hepatitis dD01970111
Hepatitis dD003699EFO_000730411
Herpesviridae infectionsD006566EFO_0007309B00.411
LipodystrophyD008060E88.111
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_0002614E88.81911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv seropositivityD00667933
AgingD000375GO_0007568R41.8111
Liver cirrhosisD008103EFO_0001422K74.011
FibrosisD00535511
Biliary liver cirrhosisD008105K74.311
Job syndromeD007589EFO_0003775D82.411
Cardiovascular diseasesD002318EFO_0000319I9811
Retinal diseasesD012164H35.911
Metabolic syndromeD024821EFO_0000195E88.81011
Drug interactionsD00434711
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTenofovir alafenamide
INNtenofovir alafenamide
Description
Tenofovir alafenamide is an L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection. It has a role as an antiviral drug, a HIV-1 reverse transcriptase inhibitor and a prodrug. It is a L-alanine derivative, a phosphoramidate ester, an ether, a member of 6-aminopurines and an isopropyl ester. It is functionally related to an adenine. It is a conjugate base of a tenofovir alafenamide(1+).
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1
Identifiers
PDB
CAS-ID379270-37-8
RxCUI
ChEMBL IDCHEMBL2107825
ChEBI ID
PubChem CID9574768
DrugBankDB09299
UNII IDEL9943AG5J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Genvoya Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Odefsey Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Vemlidy Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Descovy Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Biktarvy Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,227 documents
View more details
Safety
Black-box Warning
Black-box warning for: Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Vemlidy
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
18,585 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use